Curagen Corp Watch

from 10-Q 7 pages 1) Licensed Antigens – The Parties Hereby Agree That Each Optioned Antigen of Either Party Under the Collaboration Agreement Immediately Prior to the Date This Letter Is Acknowledged by Afi (The “Effective Date”) Shall Be Deemed a Licensed Antigen for Purposes of This Letter Agreement. the Parties Further Agree That as of the Effective Date the Curagen Licensed Antigens Consist of Those Antigens Set Forth on Schedule 1, and the Abx Licensed Antigens Consist of Those Antigens Set Forth on Schedule 2. 1

from 10-Q 2 pages Non-Employee Director Compensation Summary

from 10-K 3 pages You and Curagen Corporation (“Curagen”) Are Parties to an Employment Agreement, Entered Into as of December 14, 2007 and Effective as of January 1, 2008 (The “Employment Agreement”), Which Outlines the Terms and Conditions of Your Employment With Curagen. in Light of Recent Tax Legislation Under Section 409a of the Internal Revenue Code (“Section 409a”), You and Curagen Mutually Desire to Amend Certain Provisions of the Employment Agreement as Set Forth Below: 1. Section 11(e) Section 11(e) of the Employment Agreement Shall Be Deleted in Its Entirety and Replaced With the Following

from 10-K 3 pages You and Curagen Corporation (“Curagen”) Are Parties to an Amended and Restated Employment Agreement, Entered Into as of September 19, 2007, Which Amended and Restated the Employment Agreement Originally Dated as of September 9, 2002 (The “Employment Agreement”), Which Outlines the Terms and Conditions of Your Employment With Curagen. in Light of Recent Tax Legislation Under Section 409a of the Internal Revenue Code (“Section 409a”), You and Curagen Mutually Desire to Amend Certain Provisions of the Employment Agreement as Set Forth Below: 1. Section 11(e) Section 11(e) of the Employment Agreement Shall Be Deleted in Its Entirety and Replaced With the Following

from 10-K 3 pages You and Curagen Corporation (“Curagen”) Are Parties to an Employment Agreement, Dated September 1, 2006 (The “Employment Agreement”), Which Outlines the Terms and Conditions of Your Employment With Curagen. in Light of Recent Tax Legislation Under Section 409a of the Internal Revenue Code (“Section 409a”), You and Curagen Mutually Desire to Amend Certain Provisions of the Employment Agreement as Set Forth Below: 1. Section 11(e) Section 11(e) of the Employment Agreement Shall Be Deleted in Its Entirety and Replaced With the Following

from 10-K 2 pages Non-Employee Director Compensation Summary

from 10-K 1 page Executive Officer Compensation Summary

from 10-Q 13 pages Curagen Corporation 2007 Stock Incentive Plan Amended and Restated

from 8-K 86 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Transfer and Termination Agreement Dated as of April 21, 2008 by and Between Topotarget a/S and Curagen Corporation Transfer and Termination Agreement

from 10-K 21 pages This Employment Agreement (“Agreement”) Entered Into as of December 14, 2007 and Effective as of January 1, 2008, Between Curagen Corporation, a Corporation Organized Under the Laws of the State of Delaware, With Its Principal Place of Business at 322 East Main Street, Branford, Connecticut (The “Company”), and Sean A. Cassidy (“Executive”) to Provide for the Continued Employment of Executive. Whereas, the Executive Desires to Continue to Be Employed by the Company, Subject to the Terms and Conditions of This Agreement; and the Company Desires to Retain the Executive’s Services, Subject to the Terms and Conditions of This Agreement. Therefore, the Company and the Executive, Intending to Be Legally Bound, Hereby Agree as Follows: 1. Employment; Duties and Responsibilities

from 10-K 1 page To: David M. Wurzer, Executive Vice-President & CFO From: Timothy M. Shannon, President & CEO Date: December 20, 2007 Re: Addendum to Employment Agreement This Memo Will Serve as and Addendum to the Employment Agreement (“The Agreement”) You Executed With Your Employer, Curagen Corporation (“The Company”), on or About September 1, 2006. David M. Wurzer (“The Executive”) and the Company Have Agreed to Modify the Terms of That Agreement as Follows, Effective January 1, 2008

from 10-K 8 pages Agreement and General Release

from 10-K 1 page Non-Employee Director Compensation Summary

from 10-K 1 page Executive Officer Compensation Summary

from 10-K 4 pages Curagen Corporation Nonstatutory Stock Option Agreement Granted Under 2007 Stock Incentive Plan

from 10-Q 7 pages Curagen Corporation Restricted Stock Agreement

from 10-Q 7 pages Indemnity Agreement

from 10-Q 4 pages Assignment and Assumption of Lease With Landlord’s Consent and Release

from 10-Q 3 pages Curagen Corporation Nonstatutory Stock Option Agreement Granted Under 2007 Stock Incentive Plan

from 10-Q 24 pages This Amended and Restated Employment Agreement (“Agreement”) Entered Into as of September 19, 2007 Between Curagen Corporation, a Corporation Organized Under the Laws of the State of Delaware, With Its Principal Place of Business at 322 East Main Street, Branford, Connecticut (The “Company”), and Timothy M. Shannon, M.D. (“Executive”) Amends and Restates the Employment Agreement Originally Dated as of September 9, 2002 and Amended Thereafter, to Provide for the Continued Employment of Executive. Whereas, the Executive Desires to Continue to Be Employed by the Company, Subject to the Terms and Conditions of This Agreement; and the Company Desires to Retain the Executive’s Services, Subject to the Terms and Conditions of This Agreement. Therefore, the Company and the Executive, Intending to Be Legally Bound, Hereby Agree as Follows: 1. Employment; Duties and Responsibilities